FORM 4
--------

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup>	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer				
Zhang Jack Y.	Amphastar Pharmaceuticals, Inc. [ AMPH ]	(Check all applicable)   _X_Director _X_10% Owner				
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	X_ Officer (give title below)   Other (specify below)     CEO & Chief Scientific Officer				
C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET	2/3/2021					
(Street) <b>RANCHO CUCAMONGA, CA 91730</b> (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person				

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

142		erritative st	ceurnes r	rede		-spose	u oi, oi 20	inchenany Owned		
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	(Instr. 8) Disp		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Beneficial
			Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock	2/3/2021		S <sup>(1)</sup>		16299	D	\$18.3645 <mark>(2)</mark>	6973449		See footnote <u>(3)</u>
Common Stock	2/4/2021		s <u>(1)</u>		25570	D	\$18.8901 ( <u>4</u> )	6947879		See footnote <u>(3)</u>
Common Stock								2246988	D	
Common Stock								1449961		See footnote <u>(5)</u>
Common Stock								5000		See footnote <u>(6)</u>

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate	2.	3. Trans.	3A. Deemed	4. Trans. C	ode	5. Number	of	6. Date Exer	cisable and	7. Tit	le and Amount of	8. Price of	9. Number of	10.	11. Nature
Security	Conversion	Date	Execution	(Instr. 8)		Derivative	Securities	Expiration I	Date	Secur	ities Underlying	Derivative	derivative	Ownership	of Indirect
(Instr. 3)	or Exercise		Date, if any			Acquired (	A) or	-		Deriv	ative Security	Security	Securities	Form of	Beneficial
	Price of		-			Disposed o	f (D)			(Instr	3 and 4)	(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					(Instr. 3, 4	and 5)			-	-		Owned	Security:	(Instr. 4)
	Security												Following	Direct (D)	
								Date	Expiration		Amount or Number of		Reported	or Indirect	
								Exercisable	Date	Title	Amount or Number of Shares		Transaction(s)	(I) (Instr.	
				Code	V	(A)	(D)						(Instr. 4)	4)	

### **Explanation of Responses:**

- (1) The sales reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.09 to \$18.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).
- (3) The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust (the "BLZ Trust") are the sole owners.
- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.38 to \$19.06, inclusive.
- (5) The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
- (6) The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.

### **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director 10% Owner Officer	Other					

Zhang Jack Y. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	X	X	CEO & Chief Scientific Officer	
Luo Mary Z. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	X	X	COO,Chief Scientist & Chairman	
Applied Physics & Chemistry Laboratories, Inc. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730		X		

Signatures

/s/ Eva Wen, by power of attorney for Jack Y. Zhang		
**Signature of Reporting Person	Date	
/s/ Eva Wen, by power of attorney for Mary Z. Luo	2/5/2021	
**Signature of Reporting Person	Date	
/s/ Eva Wen, by power of attorney for Jack Y. Zhang, principal and owner of Applied Physics & Chemistry Laboratories, Inc.	2/5/2021	
**Signature of Reporting Person	Date	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.